This guide was put together using insights from individuals working directly on Pharma/CMO relationships. In each case we asked individuals how they would tackle a particular CMO crisis and have collated their insights into this handy guide. Example of a CMO crisis included in this guide is; How would you collect and react fast if a batch was rejected in order to keep the supply chain safe?
With insights from over 50 individuals within the Pharma industry, and accompanied by commentary from Ulrich Ruemenapp, Head of Launch Preparation, Bayer this report will take an in-depth look at the most important components when selecting a CMO, the greatest risks when choosing to outsource and best practises for managing CMO networks.
This report will explore:
- Which Key elements you need to prioritise to allow you to reduce your external partner footprint
- The greatest risks when choosing to outsource
- The characteristics sponsors most value in a CMO
Pharma Contract Manufacturing, the only conference dedicated to helping you manage and consolidate your external partnerships will be welcoming over 60+ head and directors of external supply and manufacturing to Berlin for 3 days of case-study led presentations, expertly guided discussion and networking.
Find out who you will meet by downloading the sample delegate list >>
Alternatively, email us at email@example.com and we'll send you a copy.
We have put together a handbook of exclusive information on some of the most pertinent issues facing the sector. This handbooks draws on the discussions of leading experts and real-life experiences shared at the 2018 Pharma Contract Manufacturing conference, and will serve as a guide to navigating the challenges of Pharma/CMO relationships and best practises for building long-lasting strategic partnerships for the future.
We spoke exclusively with Luiz Barberini, Sr. Operations Manager - External Manufacturing Latin America, Bayer about how he manages relationships with contract manufacturers.
From this discussion we have put together this handy pocket guide which covers topics including conflict management, mitigating risks and building resourceful and lasting relationships with contractors.
Nowadays, nearly 80% of drugs currently FDA approved on behalf of small bio/pharma companies are contract manufactured, and 50% of products supported by mid-size companies use a CMO. In the lead up to the Pharma Contract Manufacturing Conference, Pharma IQ have looked at the evolution of the roles of CMOs and CDMOs in the industry, and what the future will bring for these organisations.
When building a resourceful and reliable relationship with a CMO it is critical that both companies understand each other’s culture, mission and values. Pharma IQ caught up with Christophe Stevens, Associate Director External Manufacturing, UCB and Christophe Defrance, External Manufacturing Director, UCB to discuss the optimisation and consolidation of their extensive CMO network.